The closing of the transaction is at the mercy of customary closing conditions, including the approval of Zygo's stockholders and applicable regulatory approvals. Kaufman, the Chairman of the Board of Zygo, which beneficially owns approximately 23.6 percent of the outstanding shares of Zygo, and also Mr. Willis, have decided to vote their shares of Zygo common stock and only the merger.. AMETEK, Zygo enter definitive merger agreement AMETEK, Inc. and Zygo Company announced they have entered into a definitive merger contract under which AMETEK will acquire all the excellent shares of common stock of Zygo at a purchase price of $19.25 per share in cash, which represents reduced of 31 percent to Zygo'on April 10 s closing share cost, 2014.Tor Peters, CEO of Occlutech says; We are very pleased with the courts decision that once again brings clearness to Occlutech’s position that our unique patented braiding technology is normally fundamentally different from the older technology. The flexibleness and flexibility of our products and the innovative delivery systems possess helped us obtain marketplace leading positions in several markets and we plan to expand this placement over the next years. .
PRESS RELEASE DUBLINandWESTLAKE VILLAGE, Calif.,Aug. 5, 2015/PRNewswire/ –Allergan plc andKYTHERA Biopharmaceuticals, Inc. today announced that they have amended and restated their merger contract with respect toAllergan'spending acquisition of KYTHERA to provide for all-cash concern to KYTHERA's stockholders.